MedTrace Logo

Comparison of The Continous Suprainguinal Fascia Iliaca Compartment Block and Continous Epidural

NCT06636331 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-10-15

No results posted yet for this study

Summary

This study evaluates the effectiveness of postoperative analgesia quality, Interleukin-6, Hemodynamic stability and QoR-40 of continuous Suprainguinal Fascia Iliaca Compartment Block (S-FICB) compared with continuous epidural in patients undergoing cephalomedullary nailing surgery.

Half of participants will receive continuous S-FICB with patient control regional analgesia using ropivacaine 0.2% continue 2ml/hr and demand dose 5ml as needed, while the other half will receive continuous epidural with patient control epidural analgesia using same regimen.

Conditions

  • Pain, Postoperative

Interventions

OTHER

Continuous Suprainguinal Fascia Iliaca Compartment Block

Using PCRA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.

OTHER

Continuous Epidural

Using PCEA and Local Anesthetic Ropivacaine 0.2% continuous 2ml/hr and demand dose 5ml as needed.

Sponsors & Collaborators

  • Udayana University

    lead OTHER

Principal Investigators

  • Tjokorda Gde Agung Senapathi · Udayana University

  • I Gusti Ngurah Mahaalit Aribawa · Udayana University

  • I Gusti Agung Gede Utara Hartawan · Udayana University

  • I Gede Budiartha · Udayana University

  • I Made Gede Widnyana · Udayana University

  • Made Agus Kresna Sucandra · Udayana University

  • Ida Bagus Krisna Jaya Sutawan · Udayana University

  • I Putu Pramana Suarjaya · Udayana University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-20
Primary Completion
2024-10-30
Completion
2024-10-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06636331 on ClinicalTrials.gov